NFKB1 and Hodgkins lymphoma: Pharmacological inhibitors of NIK have recently been shown to trigger cell death in cancers that depend on constitutive overexpression of NIK for their survival such as Hodgkin lymphoma.22 Thus, in future studies it will be interesting to explore whether therapeutic targeting of NF-κB signaling via NIK may open new perspectives to bypass inducible resistance mechanisms to proteotoxic drugs in RMS.